Minovia Therapeutics has been granted two new US patents covering the use of its mitochondrial augmentation therapy platform in both primary mitochondrial diseases and renal disorders, strengthening the company’s intellectual property position as it advances clinical development of its lead programmes.

The newly issued patents expand protection around Minovia’s proprietary mitochondrial augmentation therapy, or MAT, which is designed to restore mitochondrial function by introducing healthy mitochondria into patient-derived cells. The company said the patents extend coverage beyond inherited mitochondrial disorders to include a range of renal indications, broadening the potential scope of the platform.

One of the patents relates specifically to the treatment of primary mitochondrial diseases and includes claims covering Minovia’s lead programme, MNV-201. The investigational therapy consists of autologous haematopoietic stem cells enriched with placental-derived mitochondria and is currently being evaluated in clinical studies for Pearson syndrome and other severe genetic mitochondrial disorders.

The second patent focuses on the use of mitochondrial augmentation therapy in renal diseases, including renal tubulopathy, kidney insufficiency and chronic kidney disease. According to the company, this protection supports the expansion of MAT into disease areas where mitochondrial dysfunction is thought to contribute to progressive organ damage.

Natalie Yivgi-Ohana, co-founder and CEO of Minovia, said: “These new patent grants strengthen and protect Minovia’s intellectual property and underscore the versatility of our proprietary mitochondrial augmentation platform across multiple serious disease areas.”

She added that securing protection across both mitochondrial and renal indications supports the company’s longer-term development plans as it continues to build out its clinical pipeline.

The newly granted US patents complement existing intellectual property already awarded in Europe and Japan, with further applications pending in other jurisdictions. Minovia said the expanded portfolio is intended to support both internal development efforts and potential future partnerships.

Mitochondrial diseases are rare, often severe conditions caused by defects in mitochondrial function, leading to impaired energy production across multiple organ systems. Current treatment options are limited and largely supportive, leaving significant unmet medical need. By targeting the underlying bioenergetic dysfunction, Minovia’s MAT platform aims to address disease mechanisms rather than symptoms alone.

In addition to its mitochondrial disease programmes, the company is continuing to explore the role of mitochondrial dysfunction in renal disorders. Chronic kidney disease and related conditions affect millions of patients globally, and mitochondrial impairment has increasingly been linked to disease progression and treatment resistance.

Separately, Minovia has previously announced a definitive business combination agreement with Launch One Acquisition Corp, a publicly traded special purpose acquisition company. Following the expected closing of the transaction in the first half of 2026, the combined company is expected to operate under the Minovia Therapeutics name and trade on Nasdaq under a new ticker symbol.

MNV-201 remains Minovia’s most advanced programme and continues to be evaluated in early-stage clinical studies. The company has reported that the therapy has shown a favourable safety profile to date, alongside early signs of potential multi-system benefit in patients with Pearson syndrome.

While the patent grants do not change the clinical or regulatory status of Minovia’s therapies, they strengthen the company’s position as it advances MAT through clinical development and explores additional therapeutic applications.